Metformina Adair (Metformin Hydrochloride)

Metformin works primarily by activating AMP‑activated protein kinase (AMPK), which suppresses liver glucose production, reduces intestinal glucose absorption, and increases insulin‑mediated glucose uptake in muscle. These actions lower blood sugar without directly stimulating insulin secretion.

The exact dose of Metformina Adair is individualized by the prescribing clinician based on the patient’s renal function, glycemic targets, and tolerability. Dosage adjustments are made during treatment to achieve optimal blood‑glucose control.

The safety of metformin during pregnancy or lactation is not fully established. Healthcare providers weigh potential benefits against risks and may continue therapy if the advantages for maternal glycemic control outweigh possible fetal exposure. Breastfeeding mothers should consult their physician.

To place an order, submit an enquiry on the Metformina Adair product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and necessary import documentation.

Metformina Adair belongs to the biguanide class, which differs from sulfonylureas, DPP‑4 inhibitors, or SGLT2 inhibitors. It does not cause insulin release, thus carries a lower risk of hypoglycemia when used alone, and may aid in weight management, whereas other classes have distinct mechanisms and side‑effect profiles.

Metformina Adair should be stored at ambient temperature, below 25 °C, in its original packaging to protect from moisture and light. Keep the product out of reach of children and do not use after the expiration date.

Metformina Adair is taken orally, usually with meals to reduce gastrointestinal discomfort. Tablets should be swallowed whole with a full glass of water. The exact timing and frequency are determined by the prescribing clinician.

The most serious risk is lactic acidosis, a rare but potentially fatal condition that can occur in patients with severe renal or hepatic impairment, excessive alcohol intake, or hypoxia. Prompt medical attention is required if symptoms such as rapid breathing, muscle pain, or abdominal discomfort develop.

Metformina Adair is contraindicated in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), acute or chronic metabolic acidosis, known hypersensitivity to metformin, or those receiving radiographic contrast studies requiring renal imaging. Clinicians should evaluate each patient’s medical history before prescribing.